Udo Rudloff, M.D., Ph.D.
Dr. Rudloff’s laboratory is working on preclinical drug development in pancreas cancer. His recent work identified novel mechanisms and genes involved in resistance to MAPK pathway inhibition, novel biomarkers predicting response to MEK and PI3K/mTOR inhibition, or an immunomodulatory anti-IL10 peptide mediating tumor regression and prolongation of survival in a transgenic animal model of pancreas cancer. Combinational experiments with gemcitabine and a TGFbeta receptor II inhibitor in transgenic animal models have shown that intratumoral gemcitabine levels rise depending on the underlying genotype of the tumor upon blockade of TGFbeta signaling.
Dr. Rudloff’s clinical expertise in HBP and pancreatic surgery supports a number of clinical and translational research efforts in patients with complex GI cancers.
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer harboring KRAS G12R MutationsOpen - RecruitingNCI Protocol ID NCI-17-C-0144Investigator Udo Rudloff, M.D., Ph.D.Share this trial: Referral Contacts
Contact Name Phone Number Marcia Mulquin 240-760-6235
Dr. Rudloff's clinical interests lie in the management of complex cancers of the liver, biliary tree, and pancreas. His laboratory efforts focus on preclinical drug development for pancreatic cancer and other gastrointestinal (GI) malignancies using in vitro and in vivo models, and the design of personalized treatment strategies for the individual genotype of patients' tumors.
Dr. Rudloff and his team.
Selected Recent Publications
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.Hum Gene Ther. 25: 1003-12, 2014. [ Journal Article ]
Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.Ann Surg Oncol. 21: 2484-9, 2014. [ Journal Article ]
- Methods Mol Biol. 1102: 461-80, 2014. [ Journal Article ]
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial.J Surg Oncol. 110: 275-84, 2014. [ Journal Article ]
- Ann Surg Oncol. 20: 555-61, 2013. [ Journal Article ]
Dr. Rudloff is an investigator and surgical oncologist at the Surgery Branch, National Cancer Institute, National Institutes of Health, in Bethesda, Maryland. Dr. Rudloff completed his M.D. at the University of Heidelberg, Germany. For his doctoral thesis at the German Cancer Research Institute, Heidelberg, he worked on gene regulation of rRNA transcription. He graduated from New York University in 2007 upon completion of his surgical residency training and pursued subspecialty training in surgical oncology by completing a 2-year surgical oncology fellowship at Memorial Sloan Kettering Center in New York City. He was appointed to the senior staff of the Surgery Branch/NCI in July 2009.
|Taylor Aiken||Guest Researcher|
|Tatiana Beresnev||Data Manager (Contr)|
|Yansong Bian||Research Biologist|
|Cara Kenney R.N.||Research Nurse Specialist|
|Zachary Knotts||Administrative Assistant (Contr)|
|Tricia F. Kunst R.N.||Research Nurse Specialist|
|Dandan Li Ph.D.||Visiting Fellow|
|Paul Nolen C.S.T.||Patient Care Coordinator|
|Rushikesh Sable Ph.D.||Postdoctoral Fellow (Visiting)|
|Yvonne Shutack||Data Manager (Contr)|